MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
about
How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancerAgreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysisPretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRINeoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy.Coregistration of dynamic contrast enhanced MRI and broadband diffuse optical spectroscopy for characterizing breast cancer.MRI in breast cancer therapy monitoringDiffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewTexture analysis on MR images helps predicting non-response to NAC in breast cancerBreast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response.Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?A role for biomarkers in the screening and diagnosis of breast cancer in younger women.Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.Role of MRI in screening, diagnosis and management of breast cancer.Integration of microwave tomography with magnetic resonance for improved breast imaging.Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopyAre we HER-ting for innovation in neoadjuvant breast cancer trial design?Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy.Treatment response assessment of breast masses on dynamic contrast-enhanced magnetic resonance scans using fuzzy c-means clustering and level set segmentationCan diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer.Evaluation of Neoadjuvant Chemotherapy Response with Dynamic Contrast Enhanced Breast Magnetic Resonance Imaging in Locally Advanced Invasive Breast CancerMeasurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.A computer-aided diagnosis (CAD) scheme for pretreatment prediction of pathological response to neoadjuvant therapy using dynamic contrast-enhanced MRI texture features.Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy.Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
P2860
Q26798419-C489AD80-C352-4DA7-9DD4-6A8E10C1CBEDQ30401252-F808658F-9876-42B3-95CD-4652EBB5D24AQ30930689-1B58B5C9-43F5-4FEA-B689-88FAABABEAB9Q31032006-456C8215-3D24-4014-9292-06E0D10743D8Q33223642-D1D3D8AC-26A4-4D0C-824B-AF983F8D4639Q33938324-A9A91357-8B52-400B-9DA3-3EAA9E70924CQ34050338-FEB5C069-520D-4888-9FF8-24687F4A4501Q34331734-3B17D26C-4B7F-4D74-938E-9299E62A9855Q34566213-E25D07C5-D754-4550-9211-A2A078F92D6AQ35737991-C810509A-920A-48DB-8DEB-F16BD458FA1AQ35804283-9DE84E2A-2B3E-4F7B-AEDD-CF88E03FAC9FQ36041569-D9EFE6F7-5EB4-47B2-8025-0659FE096C56Q36694909-0FD21B47-AA84-4260-B72D-5E72C31D9A21Q36950426-9658F65F-7902-478B-B45E-F5029787551DQ37121648-DA753AA2-3CCF-4EE6-8044-33EBFCD74B34Q37159543-E5435610-B2A9-4146-9198-4A0412AC8440Q37203314-095FCE8A-1EF8-4565-9A88-EF8696BA5C58Q37204989-39B4FB52-7D96-4BC4-B217-73CCFA540547Q37205521-038DDBB5-E58B-4F8D-9E94-4258825C8913Q37300368-91EB3D17-F4CF-4FC1-8FA8-33609CF6F511Q37385321-EDB56E62-BCF1-41F6-BE72-5CC5C440B78AQ37412241-AF226799-5376-4BC0-80B5-E4B72E20D6ABQ38000076-CC2E1542-976B-49F5-A67A-87E220DC9FB1Q38366389-E2F90F78-8F62-4844-AA6C-85BAFE3B5F9CQ42028709-EC720076-C10C-4B33-8590-F6AC72D2E199Q44354897-517424F7-95FD-424A-97ED-6533D2B806F0Q44491240-517E6913-0237-4E9F-945A-7759893F8420Q47270657-3B724A24-0FD0-4B2D-BE51-CA3262A7F309Q47766584-14BE095B-D011-4D0E-9E80-F6F7D8D2236CQ50172829-179C0444-82FA-4983-98C5-F6289E7024D7Q54446011-9552496A-71A1-45C6-AB9A-BDA3265A9798
P2860
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
MRI phenotype is associated wi ...... py in stage III breast cancer.
@en
type
label
MRI phenotype is associated wi ...... py in stage III breast cancer.
@en
prefLabel
MRI phenotype is associated wi ...... py in stage III breast cancer.
@en
P2093
P1476
MRI phenotype is associated wi ...... py in stage III breast cancer.
@en
P2093
Esserman L
Partridge S
Sudilovsky D
P2888
P304
P356
10.1007/S10434-001-0549-8
P577
2001-07-01T00:00:00Z
P5875
P6179
1024954651